Asahi Kasei Pharma has filed an application for import drug registration in China for Flivas™ (naftopidil), an agent for the treatment of dysuria associated with benign prostatic hyperplasia (BPH), on June 2, 2017.

BPH is a condition in which an enlarged prostate gland causes urinary symptoms such as discomfort, incontinence, incomplete voiding, and nocturia. Naftopidil is an α1-blocker that suppresses the constriction of smooth muscle in the prostate gland and in the urethra, alleviating the discomfort and other symptoms of BPH. It has been sold in Japan since February 1999.

Asahi Kasei Pharma hopes that naftopidil will provide a new treatment option for treating dysuria associated with BPH in China.

Product overview

Product name

福列® in Chinese, Flivas® (planned)

Generic name

Naftopidil

Indication

Dysuria associated with benign prostatic hyperplasia (planned)

Formulation

Tablets (25 mg and 50 mg)